Simulations Plus, Inc. (SLP)

48,01 -0,53 (-1,09%) Alla chiusura: 04:00PM EDT

Simulations Plus, Inc.

42505 Tenth Street West
Lancaster, CA 93534-7059
United States
661 723 7723
https://www.simulations-plus.com

Settore/i: Healthcare
Settore: Health Information Services
Impiegati a tempo pieno: 192

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Walter S. Woltosz M.A.S., M.S.	Co-Founder & Chairman	80k	N/D	1945
Mr. Shawn M. O'Connor	Chief Executive Officer	847,56k	N/D	1960
Mr. William Frederick	COO, CFO & Secretary	443,12k	1,29k	1964
Mr. John Anthony DiBella M.S.	President of PBPK & Cheminformatics Solutions	399,8k	2,13M	1980
Dr. Brett A. Howell Ph.D.	President of Quantitative Systems Pharmacology Solutions	321,67k	N/D	1984
Ms. Jill Fiedler-Kelly M.S.	President of Clinical Pharmacology & Pharmacometrics Services	393,77k	17,43k	1969
Ms. Viera Lukacova Ph.D.	Chief Science Officer	N/D	N/D	N/D
Dr. Bud Nelson J.D., Ph.D.	VP of Corporate Counsel & Personal Data Protection Officer	N/D	N/D	N/D
Ms. Arlene Padron	Corporate Director of Marketing	N/D	N/D	N/D
Dr. Scott Q. Siler	Chief Scientific Officer of DILIsym Services, Inc	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Governance aziendale

L'ISS Governance QualityScore di Simulations Plus, Inc. al 1 maggio 2024 è 2. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 5; diritti degli azionisti: 1; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.